We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Drugmakers have often lambasted the U.S. Patent and Trademark Office’s (PTO's) inter partes review system, but now Gilead Sciences is hoping to use it to its advantage.